National Center for Advancing Translational Sciences#Divisions

NCATS was created on December 23, 2011 by the Consolidated Appropriations Act, 2012.{{Cite web |url=http://www.ncats.nih.gov/about/budget/authorization.html |title=Authorization |access-date=2014-03-16 |archive-url=https://web.archive.org/web/20140316225240/http://www.ncats.nih.gov/about/budget/authorization.html |archive-date=2014-03-16 |url-status=dead }}

The center was created from a number of existing NIH programs:{{cite journal|title=US translational-science centre gets under way|first=Meredith|last=Wadman|date=12 January 2012|journal=Nature|volume=481|issue=7380|pages=128|doi=10.1038/481128a|pmid=22237088|bibcode=2012Natur.481..128W |doi-access=free}}

• Clinical and Translational Science Award program
• Components of the Molecular Libraries Program
• Therapeutics for Rare and Neglected Diseases
• RAID renamed Bridging Interventional Development Gaps
• Office of Rare Diseases Research
• NIH–FDA Regulatory Science Initiative
• Cures Acceleration Network (CAN){{cite web|url=http://rareadvocates.org/nihs-cures-acceleration-network-can/|title=NIH's Cures Acceleration Network (CAN) – Rare Disease Legislative Advocates|date=12 May 2010}}{{cite web|url=http://www.ncats.nih.gov/advisory/canboard|title=Cures Acceleration Network (CAN) Review Board – National Center for Advancing Translational Sciences|website=National Center for Advancing Translational Sciences|date=13 March 2015 }}

Past directors 2011 – present{{cite web|title=NCATS Directors|url=https://www.nih.gov/about-nih/what-we-do/nih-almanac/national-center-advancing-translational-sciences-ncats|website=www.nih.gov|date=10 July 2015 }}

NCATS is organized into a number of divisions:

• Division of Clinical Innovation
• Division of Pre-Clinical Innovation
• Office of Administrative Management
• Office of Grants Management and Scientific Review
• Office of Rare Diseases Research: Oversees the Rare Diseases Clinical Research Network and Genetic and Rare Diseases Information Center (GARD)
• Office of Strategic Alliances: Works with businesses in the biotech and pharmaceutical industry to speed the development of new drugs{{cite web|url=https://ncats.nih.gov/about/center/org|title=Divisions & Offices|date=12 March 2015|website=National Center for Advancing Translational Sciences}}

The stated goal of NCATS is to promote research in both existing and new areas of medicine and science, in order to promote public health and to overcome high failure rates in clinical trials.{{Cite web|date=2017-10-30|title=About NCATS|url=https://ncats.nih.gov/about|access-date=2021-10-20|website=National Center for Advancing Translational Sciences|language=en}}{{Cite journal|last1=Sacks|first1=Leonard V.|last2=Shamsuddin|first2=Hala H.|last3=Yasinskaya|first3=Yuliya I.|last4=Bouri|first4=Khaled|last5=Lanthier|first5=Michael L.|last6=Sherman|first6=Rachel E.|date=2014-01-22|title=Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000–2012|journal=JAMA|volume=311|issue=4|pages=378–384|doi=10.1001/jama.2013.282542|pmid=24449316 |issn=0098-7484|doi-access=free}} To accomplish this, NCATS supports 31 programs and initiatives that relate to translational research and improving the speed of therapeutic development.{{Cite web|date=2015-03-16|title=NCATS Programs & Initiatives|url=https://ncats.nih.gov/programs|access-date=2021-09-28|website=National Center for Advancing Translational Sciences|language=en}} The 31 programs and initiatives involve a range of STEM-related fields including biology, biochemistry, chemistry, bioengineering, virology, genetics, and data science.{{Cite web|date=2015-03-16|title=NCATS Programs & Initiatives|url=https://ncats.nih.gov/programs|access-date=2021-10-20|website=National Center for Advancing Translational Sciences|language=en}} Within the realm of translational science, issues that NCATS is particularly focused on addressing using its programs, initiatives, and partnerships include increasing the success and de-risking the costs associated with therapeutic development, incentivizing more collaborative work, and addressing data transparency issues.{{Cite web|date=2015-03-12|title=Issues in Translation|url=https://ncats.nih.gov/translation/issues|access-date=2021-10-20|website=National Center for Advancing Translational Sciences|language=en}}

During the COVID-19 pandemic, NCATS launched an open data initiative to promote collaborative sharing of COVID-related drug data.{{Cite web|date=2020-06-08|title=COVID-19 OpenData Portal|url=https://ncats.nih.gov/expertise/covid19-open-data-portal|access-date=2021-10-01|website=National Center for Advancing Translational Sciences|language=en}} An additional data sharing partnership with several other government institutes resulted in a study detailing the COVID-related risks for patients with chronic obstructive pulmonary disease.{{Cite web|date=2021-09-23|title=N3C Data Reveals COVID-19's Stark Mortality Risk in People with COPD|url=https://ncats.nih.gov/pubs/features/national-ehr-data-resource-reveals-covid-19-stark-mortality-risk-in-people-with-copd|access-date=2021-10-01|website=National Center for Advancing Translational Sciences|language=en}}{{Cite journal|last1=Meza|first1=Daniel|last2=Khuder|first2=Basil|last3=Bailey|first3=Joseph I|last4=Rosenberg|first4=Sharon R|last5=Kalhan|first5=Ravi|last6=Reyfman|first6=Paul A|date=August 2021|title=Mortality from COVID-19 in Patients with COPD: A US Study in the N3C Data Enclave|journal=International Journal of Chronic Obstructive Pulmonary Disease|volume=16|pages=2323–2326|pmid=34413640|doi=10.2147/copd.s318000|pmc=8370846|issn=1178-2005 |doi-access=free }}

• Translational research

{{reflist}}

{{National Institutes of Health}}

{{authority control}}

{{coord missing|Maryland}}

Category:National Institutes of Health

Category:Medical research institutes in Maryland